Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)
Others
Ratios

CASI Pharmaceuticals (CASI) Cost of Revenue (2022 - 2025)

Historic Cost of Revenue for Pharmaceuticals (CASI) over the last 4 years, with Q2 2025 value amounting to $5.0 million.

  • Pharmaceuticals' Cost of Revenue rose 1209.04% to $5.0 million in Q2 2025 from the same period last year, while for Jun 2025 it was $13.6 million, marking a year-over-year increase of 2290.26%. This contributed to the annual value of $17.4 million for FY2024, which is 2577.57% up from last year.
  • Latest data reveals that Pharmaceuticals reported Cost of Revenue of $5.0 million as of Q2 2025, which was up 1209.04% from $2.6 million recorded in Q1 2025.
  • Pharmaceuticals' 5-year Cost of Revenue high stood at $5.6 million for Q4 2022, and its period low was $1.6 million during Q1 2024.
  • Moreover, its 4-year median value for Cost of Revenue was $3.4 million (2022), whereas its average is $3.6 million.
  • As far as peak fluctuations go, Pharmaceuticals' Cost of Revenue tumbled by 5476.19% in 2023, and later soared by 6350.59% in 2025.
  • Over the past 4 years, Pharmaceuticals' Cost of Revenue (Quarter) stood at $5.6 million in 2022, then crashed by 54.76% to $2.5 million in 2023, then soared by 75.11% to $4.4 million in 2024, then grew by 12.09% to $5.0 million in 2025.
  • Its last three reported values are $5.0 million in Q2 2025, $2.6 million for Q1 2025, and $4.4 million during Q2 2024.